de la Espriella R, Bayés‐Genís A, Morillas H, et al. - Researchers conducted this multicentre observational analysis to assess the safety profile in terms of changes in renal function after co‐treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). The sample consisted of 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). Sacubitril/valsartan and empagliflozin co-administration tend to be safe in terms of renal function in patients with HFrEF and concomitant T2D.